Observational studyFrontiers in immunology2026

Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing.

Alex Agundez-Moreno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.